| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| Targets |
OX2 Receptor 0.028 μM (EC50) OX1 Receptor 2.75 μM (EC50)
|
|---|---|
| ln Vivo |
Mice treated with YNT-185 dihydrochloride (20–40 mg/kg; ip) show increased wakefulness[2]. In wild-type mice, but not in OXRDKO mice, YNT-185 dihydrochloride (300 nmol; icv) dose-dependently and dose-dependently increases wake time for three hours, accompanied by a reduction in NREM sleep time[2].
|
| Animal Protocol |
Animal/Disease Models: Male wild-type C57BL/6J mice[2]
Doses: 20, 40 mg/kg Route of Administration: Ip Experimental Results: Wake time was also Dramatically increased. |
| References |
[1]. Nagahara T, et al. Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists. J Med Chem. 2015;58(20):7931-7937.
[2]. Irukayama-Tomobe Y, et al. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. Proc Natl Acad Sci U S A. 2017;114(22):5731-5736. |
| Molecular Formula |
C33H39CL2N5O5S
|
|---|---|
| Molecular Weight |
688.66
|
| CAS # |
1804978-82-2
|
| Related CAS # |
YNT-185;1804978-81-1
|
| SMILES |
Cl.Cl.S(C1C(=CC=C(C2C=CC=C(C(N(C)C)=O)C=2)C=1)OC)(NC1C=CC=C(C=1)NCCNC(C1C=CC=CC=1N(C)C)=O)(=O)=O
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (181.51 mM)
H2O: 100 mg/mL (145.21 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 12.5 mg/mL (18.15 mM) in Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4521 mL | 7.2605 mL | 14.5210 mL | |
| 5 mM | 0.2904 mL | 1.4521 mL | 2.9042 mL | |
| 10 mM | 0.1452 mL | 0.7260 mL | 1.4521 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
